ACRV Profile
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision oncology medicines. The company leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to match patients with tumors predicted to be sensitive to specific therapies. This platform utilizes proteomics-based patient responder identification to create drug-specific OncoSignature companion diagnostics, which help identify patients likely to benefit from Acrivon's drug candidates.
The company's lead clinical candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2. ACR-368 is currently in a potentially registrational Phase 2 trial, being tested across various tumor types. The trial aims to establish the efficacy and safety of ACR-368 in treating cancers that have been identified as responsive to this targeted therapy using the AP3 platform.
In addition to ACR-368, Acrivon is advancing a robust pipeline of preclinical programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways. These include inhibitors of WEE1 and PKMYT1, which play crucial roles in cell cycle checkpoints and DNA repair mechanisms. These programs aim to provide new therapeutic options for patients with cancer types that are particularly reliant on these pathways for survival and proliferation.
Founded in 2018 and headquartered in Watertown, Massachusetts, Acrivon Therapeutics is committed to transforming the treatment landscape for cancer patients through its innovative precision oncology approach. By combining cutting-edge proteomics with targeted drug development, the company seeks to enhance the precision and effectiveness of cancer treatments, ultimately improving patient outcomes.
|
